After HER2 binding and internalization, the ADC releases deruxtecan, which inhibits Topoisomerase I in recipient cells, causing DNA damage and apoptosis. Top1 is the intracellular payload target, not the binding antigen, so killing is indirect with respect to Top1 expression.